BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Metrics to compare | BLLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLLNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −379.5x | −18.6x | −0.5x | |
PEG Ratio | - | −1.04 | 0.00 | |
Price/Book | −17.6x | 2.2x | 2.6x | |
Price / LTM Sales | 16.6x | 1.2x | 3.3x | |
Upside (Analyst Target) | 56.9% | 26.4% | 44.3% | |
Fair Value Upside | Unlock | 16.6% | 4.9% | Unlock |